Come up with a name for your new list and we'll add to it:
Escalier Biosciences raised a round of funding on March 20, 2017. Investors include
New Science Ventures.
Escalier Biosciences is developing both topical and oral RORyt inverse agnostics for the treatment of a broad spectrum of psoriasis patients - from the underserved mild-to-moderate patients that would…